NVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the user's beginner level, long-term investment preference, and the lack of strong immediate buy signals, Novartis AG (NVS) is not a compelling buy at this moment. While the stock has positive long-term potential due to its pipeline and analyst optimism, the recent financial performance, neutral technical indicators, and lack of strong trading trends suggest waiting for a more attractive entry point.
The MACD is positive but contracting, RSI is neutral at 31.273, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near a key support level (S1: 150.285), and the pivot level is 152.989, indicating limited immediate upside potential.
Analysts have raised price targets recently, with several firms maintaining Buy or Overweight ratings.
Novartis CEO's appointment to Anthropic's board highlights potential innovation in AI-driven healthcare solutions.
The company has a strong pipeline with significant upside potential, particularly with remibrutinib.
Recent financial performance shows declining net income (-14.51% YoY) and EPS (-11.43% YoY).
Options data indicates bearish sentiment.
Stock trend analysis predicts a potential decline in the next week (-2.72%) and month (-3.01%).
In Q4 2025, revenue increased by 2.23% YoY to $13.86 billion, but net income dropped by 14.51% YoY to $2.41 billion. EPS also declined by 11.43% YoY to 1.24, and gross margin fell slightly to 74.44%.
Analysts are generally optimistic, with recent upgrades in price targets (e.g., Morgan Stanley to $170, BofA to $178, Argus to $180). However, some firms, like Bernstein, have expressed concerns about long-term sales declines post-2031, and HSBC maintains a Reduce rating due to macroeconomic risks.
